Form 4: Entrada CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 8,910 shares of common stock for approximately $9.98 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), sold 8,910 shares of common stock.
• The transaction occurred on November 21, 2025.
• The shares were sold at a weighted average price of $9.9811 per share, with individual transaction prices ranging from $9.95 to $10.05.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Wentworth on March 6, 2025.
• Following this transaction, Mr. Wentworth beneficially owns 110,026 shares of Entrada Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be seen negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on new, non-public information. It's a routine disclosure for a planned transaction.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information and was a scheduled event.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity exposure, which can sometimes be perceived as a minor negative signal by the market.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects a planned equity management activity by a company executive.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor reduction in insider alignment, though the pre-arranged nature of the 10b5-1 plan lessens any negative implications. The transaction represents a small fraction of the company's total outstanding shares.

Key Dates

Recommendation

The filing details a pre-planned insider sale by the CFO, which is a routine event under a 10b5-1 plan. This type of transaction typically does not signal a change in the company's fundamental outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring broader company performance and market conditions.

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Sale, CFO, Kory James Wentworth, 10b5-1 Plan, Equity Transaction